BR112022016049A2 - Ligantes de proteína de ativação de fibroblastos para aplicações de liberação direcionada - Google Patents

Ligantes de proteína de ativação de fibroblastos para aplicações de liberação direcionada

Info

Publication number
BR112022016049A2
BR112022016049A2 BR112022016049A BR112022016049A BR112022016049A2 BR 112022016049 A2 BR112022016049 A2 BR 112022016049A2 BR 112022016049 A BR112022016049 A BR 112022016049A BR 112022016049 A BR112022016049 A BR 112022016049A BR 112022016049 A2 BR112022016049 A2 BR 112022016049A2
Authority
BR
Brazil
Prior art keywords
fap
activation protein
fibroblast activation
targeted release
protein binders
Prior art date
Application number
BR112022016049A
Other languages
English (en)
Inventor
Biancofiore Ilaria
Cazzamalli Samuele
Dakhel Plaza Sheila
J Donckele Etienne
Millul Jacopo
Samain Florent
Schmidt Eleonore
Original Assignee
Philochem Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philochem Ag filed Critical Philochem Ag
Priority claimed from PCT/EP2021/053494 external-priority patent/WO2021160825A1/en
Publication of BR112022016049A2 publication Critical patent/BR112022016049A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LIGANTES DE PROTEÍNA DE ATIVAÇÃO DE FIBROBLASTOS PARA APLICAÇÕES DE LIBERAÇÃO DIRECIONADA. A presente invenção se refere a ligantes de Proteína de Ativação de Fibroblastos (FAP) para a liberação ativa de várias cargas úteis (por exemplo, fármacos citotóxicos, radionuclídeos, fluoróforos, proteínas e imunomoduladores) no sítio da doença. Em particular, a presente invenção se refere ao desenvolvimento de ligantes de FAP para aplicações de direcionamento, em particular métodos de diagnóstico e/ou métodos para terapia ou cirurgia em relação a uma doença ou transtorno, tal como câncer, inflamação ou uma outra doença caracterizada pela superexpressão de FAP.
BR112022016049A 2020-02-12 2021-02-12 Ligantes de proteína de ativação de fibroblastos para aplicações de liberação direcionada BR112022016049A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20157036 2020-02-12
EP20172953 2020-05-05
EP20202856 2020-10-20
PCT/EP2021/053494 WO2021160825A1 (en) 2020-02-12 2021-02-12 Fibroblast activation protein ligands for targeted delivery applications

Publications (1)

Publication Number Publication Date
BR112022016049A2 true BR112022016049A2 (pt) 2022-11-16

Family

ID=83225945

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016049A BR112022016049A2 (pt) 2020-02-12 2021-02-12 Ligantes de proteína de ativação de fibroblastos para aplicações de liberação direcionada

Country Status (8)

Country Link
JP (1) JP2023514275A (pt)
KR (1) KR20220154111A (pt)
CN (1) CN115335370A (pt)
AU (1) AU2021220663A1 (pt)
BR (1) BR112022016049A2 (pt)
CA (1) CA3171025A1 (pt)
IL (1) IL295571A (pt)
MX (1) MX2022009931A (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116925041A (zh) * 2023-06-12 2023-10-24 上海交通大学医学院附属仁济医院 靶向成纤维细胞激活蛋白的氟标记放射性药物前体、放射性标记化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006128A (es) * 2017-12-15 2020-09-21 Praxis Biotech LLC Inhibidores de la proteina de activacion de fibroblastos.
AU2019219057B2 (en) * 2018-02-06 2022-11-24 Universität Heidelberg FAP inhibitor

Also Published As

Publication number Publication date
KR20220154111A (ko) 2022-11-21
AU2021220663A1 (en) 2022-10-06
CA3171025A1 (en) 2021-08-19
JP2023514275A (ja) 2023-04-05
CN115335370A (zh) 2022-11-11
MX2022009931A (es) 2022-09-12
IL295571A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
BR112023015831A2 (pt) Ligantes de proteína de ativação de fibroblastos bivalentes para aplicações de liberação direcionada
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
BR112018002130A2 (pt) anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)
MX2022015748A (es) Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer.
CL2021000873A1 (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
BR112019008854A2 (pt) ligantes contendo peptídeo para conjugados de anticorpo-fármaco
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
BR112022003589A2 (pt) Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo
BR112015006828A2 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar uma doença em um paciente em necessidade do tratamento; e método para modular a atividade de uma proteína ire1
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
EP2949344A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
EP3001813A4 (en) Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer